Fukiko Nishisaka Selected Research

YHO-1701

1/2021	Efficacy of combination treatment using YHO-1701, an orally active STAT3 inhibitor, with molecular-targeted agents on cancer cell lines.
5/2020	Antitumor activity of a novel oral signal transducer and activator of transcription 3 inhibitor YHO-1701.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Fukiko Nishisaka Research Topics

Disease

4	Neoplasms (Cancer) 01/2021 - 05/2017
1	Neoplasm Metastasis (Metastasis) 01/2021
1	Hematologic Neoplasms (Hematological Malignancy) 01/2021
1	Body Weight (Weight, Body) 01/2021
1	Carcinoma (Carcinomatosis) 01/2021
1	Mouth Neoplasms (Oral Cancer) 05/2020

Drug/Important Bio-Agent (IBA)

2	YHO-1701IBA 01/2021 - 05/2020
2	STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)IBA 01/2021 - 05/2020
1	proto-oncogene proteins pimIBA 01/2021
1	alectinibIBA 01/2021
1	Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA 01/2021
1	methanesulfonic acid (methanesulfonate)IBA 01/2021
1	Phosphotransferases (Kinase)IBA 01/2021
1	ThiazolidinedionesIBA 01/2021
1	SurvivinIBA 05/2020
1	STX-0119IBA 05/2020
1	Transcription Factors (Transcription Factor)IBA 05/2017
1	Proteins (Proteins, Gene)FDA Link 05/2017

Therapy/Procedure

1	Therapeutics 05/2017